Praxis Precision Medicines to Present at Upcoming Investor Conferences

Rhea-AI Summary

BOSTON, March 3, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines (NASDAQ: PRAX), focused on CNS disorders, will participate in key investor conferences. They will take part in the 43rd Annual TD Cowen Health Care Conference on March 6, 2023, featuring a panel on orphan epilepsies at 12:50 p.m. ET. Additionally, Praxis will join the Needham Neuroscience Forum for a fireside chat on March 15, 2023, at 2:00 p.m. ET. Both events will be accessible via live webcast on their website, with replays available for 30 days post-event. Praxis is advancing therapies for neurological disorders using its proprietary platforms.

BOSTON, March 03, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that management will participate in the following upcoming investor conferences:

• 43^rd Annual TD Cowen Health Care Conference
  • Orphan epilepsies panel on Monday, March 6, 2023 at 12:50 p.m. ET
    
    
• Needham Neuroscience Forum
  • Fireside chat on Wednesday, March 15, 2023 at 2:00 p.m. ET

The events will be available via live webcast through the Events & Presentations page of the Investors + Media section of the company’s website at www.praxismedicines.com. Replays of the webcasts will be available on Praxis’ website for at least 30 days following the events.

About Praxis
Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating insights from genetic epilepsies into the development of therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance. Praxis is applying genetic insights to the discovery and development of therapies for rare and more prevalent neurological disorders through our proprietary small molecule platform, Cerebrum™, and antisense oligonucleotide (ASO) platform, Solidus™, using our understanding of shared biological targets and circuits in the brain. Praxis has established a diversified, multimodal CNS portfolio including multiple programs across movement disorders and epilepsy, with four clinical-stage product candidates. For more information, please visit www.praxismedicines.com and follow us on LinkedIn and Twitter.

FAQ

What conferences will Praxis Precision Medicines participate in March 2023?

Praxis Precision Medicines will participate in the 43rd Annual TD Cowen Health Care Conference on March 6, 2023, and the Needham Neuroscience Forum on March 15, 2023.

When is the orphan epilepsies panel at the TD Cowen Health Care Conference?

The orphan epilepsies panel at the TD Cowen Health Care Conference will be on March 6, 2023, at 12:50 p.m. ET.

What time is the fireside chat at the Needham Neuroscience Forum?

The fireside chat at the Needham Neuroscience Forum is scheduled for March 15, 2023, at 2:00 p.m. ET.

How can I watch the Praxis Precision Medicines conference webcasts?

The events will be available via live webcast on the Investors + Media section of the Praxis website, with replays accessible for 30 days after the events.

What is the focus of Praxis Precision Medicines?

Praxis Precision Medicines is focused on developing therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance.